CoChat

Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1

Open access

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Abstract

In rodent models of depression, (R)-ketamine has greater potency and longer-lasting antidepressant effects than (S)-ketamine; however, the precise molecular mechanisms underlying the antidepressant actions of (R)-ketamine remain unknown. Using RNA-sequencing analysis, we identified novel molecular targets that contribute to the different antidepressant effects of the two enantiomers. Either (R)-ketamine (10 mg/kg) or (S)-ketamine (10 mg/kg) was administered to susceptible mice after chronic social defeat stress (CSDS). RNA-sequencing analysis of prefrontal cortex (PFC) and subsequent GSEA (gene set enrichment analysis) revealed that transforming growth factor (TGF)-β signaling might contribute to the different antidepressant effects of the two enantiomers. (R)-ketamine, but not (S)-ketamine, ameliorated the reduced expressions of Tgfb1 and its receptors (Tgfbr1 and Tgfbr2) in the PFC and hippocampus of CSDS susceptible mice. Either pharmacological inhibitors (i.e., RepSox and SB431542) or neutralizing antibody of TGF-β1 blocked the antidepressant effects of (R)-ketamine in CSDS susceptible mice. Moreover, depletion of microglia by the colony-stimulating factor 1 receptor (CSF1R) inhibitor PLX3397 blocked the antidepressant effects of (R)-ketamine in CSDS susceptible mice. Similar to (R)-ketamine, the recombinant TGF-β1 elicited rapid and long-lasting antidepressant effects in animal models of depression. Our data implicate a novel microglial TGF-β1-dependent mechanism underlying the antidepressant effects of (R)-ketamine in rodents with depression-like phenotype. Moreover, TGF-β1 and its receptor agonists would likely constitute a novel rapid-acting and sustained antidepressant in humans.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41398-020-0733-x

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Schedule of CSDS, treatment, RNA-sequencing analysis, and gene expression. a The schedule of chronic social defeat stress (CSDS) model, treatment, and collection of brain. b GSEA: TGF-β signaling. c Tgfb1 mRNA in the PFC (one-way ANOVA, F3,20 = 10.827, P < 0.001). d Tgfb2 mRNA in the PFC (one-way ANOVA, F3,20 = 1.795, P = 0.181). e Tgfbr1 mRNA in the PFC (one-way ANOVA, F3,20 = 5.175, P = 0.008). f Tgfbr2 mRNA in the PFC (one-way ANOVA, F3,20 = 6.801, P = 0.002). Data are shown as mean ± SEM. (n = 6). *P < 0.05, **P < 0.01. ANOVA, analysis of variance; GSEA gene set enrichment analysis, N.S. not significant, R-KT (R)-ketamine, S-KT (S)-ketamine.
Fig. 1 Schedule of CSDS, treatment, RNA-sequencing analysis, and gene expression. a The schedule of chronic social defeat stress (CSDS) model, treatment, and collection of brain. b GSEA: TGF-β signaling. c Tgfb1 mRNA in the PFC (one-way ANOVA, F3,20 = 10.827, P < 0.001). d Tgfb2 mRNA in the PFC (one-way ANOVA, F3,20 = 1.795, P = 0.181). e Tgfbr1 mRNA in the PFC (one-way ANOVA, F3,20 = 5.175, P = 0.008). f Tgfbr2 mRNA in the PFC (one-way ANOVA, F3,20 = 6.801, P = 0.002). Data are shown as mean ± SEM. (n = 6). *P < 0.05, **P < 0.01. ANOVA, analysis of variance; GSEA gene set enrichment analysis, N.S. not significant, R-KT (R)-ketamine, S-KT (S)-ketamine.CC BY · PubMed Central
Fig. 2 Effects of TGF-β1 inhibitors (RepSox and SB431542) and neutralizing TGF-β1 antibody on antidepressant effects of (R)-ketamine in CSDS model. a Locomotion (1 h, one-way ANOVA, F4,35 = 0.146, P = 0.964). b TST (3 h, one-way ANOVA, F4,35 = 5.439, P = 0.002). c FST (1 day, one-way ANOVA, F4,35 = 2.919, P = 0.035). d SPT (2 days, one-way ANOVA, F4,35 = 7.011, P < 0.001). Data are shown as mean ± SEM. (n = 8). *P < 0.05, **P < 0.01. e Locomotion (1 h, one-way ANOVA, F4,35 = 0.299, P = 0.877). f TST (3 h, one-way ANOVA, F4,35 = 16.586, P < 0.001). g FST (1 day, one-way ANOVA, F4,35 = 4.686, P = 0.004). h SPT (2 day, one-way ANOVA, F4,35 = 6.161, P = 0.001). i Locomotion (1 h, one-way ANOVA, F4,25 = 0.020, P = 0.999). j TST (3 h, one-way ANOVA, F4,35 = 8.165, P < 0.001). k FST (1 day, one-way ANOVA, F4,35 = 4.012, P = 0.015). l SPT (2 day, one-way ANOVA, F4,35 = 3.872, P = 0.021). Data are shown as mean ± SEM. (n = 8). *P < 0.05, **P < 0.01. ANOVA analysis of variance, CA control antibody, FST forced swimming test, NA neutralizing antibody, N.S. not significant, R-KT (R)-ketamine, SB SB431542, SPT sucrose preference test, TST tail suspension test.
Fig. 2 Effects of TGF-β1 inhibitors (RepSox and SB431542) and neutralizing TGF-β1 antibody on antidepressant effects of (R)-ketamine in CSDS model. a Locomotion (1 h, one-way ANOVA, F4,35 = 0.146, P = 0.964). b TST (3 h, one-way ANOVA, F4,35 = 5.439, P = 0.002). c FST (1 day, one-way ANOVA, F4,35 = 2.919, P = 0.035). d SPT (2 days, one-way ANOVA, F4,35 = 7.011, P < 0.001). Data are shown as mean ± SEM. (n = 8). *P < 0.05, **P < 0.01. e Locomotion (1 h, one-way ANOVA, F4,35 = 0.299, P = 0.877). f TST (3 h, one-way ANOVA, F4,35 = 16.586, P < 0.001). g FST (1 day, one-way ANOVA, F4,35 = 4.686, P = 0.004). h SPT (2 day, one-way ANOVA, F4,35 = 6.161, P = 0.001). i Locomotion (1 h, one-way ANOVA, F4,25 = 0.020, P = 0.999). j TST (3 h, one-way ANOVA, F4,35 = 8.165, P < 0.001). k FST (1 day, one-way ANOVA, F4,35 = 4.012, P = 0.015). l SPT (2 day, one-way ANOVA, F4,35 = 3.872, P = 0.021). Data are shown as mean ± SEM. (n = 8). *P < 0.05, **P < 0.01. ANOVA analysis of variance, CA control antibody, FST forced swimming test, NA neutralizing antibody, N.S. not significant, R-KT (R)-ketamine, SB SB431542, SPT sucrose preference test, TST tail suspension test.CC BY · PubMed Central
Fig. 3 In situ hybridization and immunohistochemistry. a Representative image of Tgfb1 mRNA (purple) and Iba1 protein (brown, marker for microglia) or S100b protein (brown, marker for astrocyte). b Representative image of Tgfbr1 mRNA. c Representative image of Tgfbr2 mRNA. Tgfb1 and its receptors (Tgfbr1 and Tgfbr2) are co-localized with microglia, but not astrocytes. Scale bar = 100 μm.
Fig. 3 In situ hybridization and immunohistochemistry. a Representative image of Tgfb1 mRNA (purple) and Iba1 protein (brown, marker for microglia) or S100b protein (brown, marker for astrocyte). b Representative image of Tgfbr1 mRNA. c Representative image of Tgfbr2 mRNA. Tgfb1 and its receptors (Tgfbr1 and Tgfbr2) are co-localized with microglia, but not astrocytes. Scale bar = 100 μm.CC BY · PubMed Central
Fig. 4 FACS analysis of PFC samples from vehicle or PLX3397 treated mice. a FACS analysis of CD11b-gated cells stained with antibody to TMEM119 in PFC samples of control mice and PLX3397 treated mice. b Iba1 and TGF-β1 expression in TMEM119+CD11b+ microglia were analyzed. Red histograms indicate control group and blue histograms indicate PLX3397 treated group. c The fluorescence intensity of both Iba1 and TGF-β1 in TMEM119+CD11b+ microglia in the PFC of PLX3397 treated mice was significantly (Iba1: P = 0.0186, TGF-β1: P = 0.0002) lower than that of control mice. d Western blot analysis of Iba1 in the PFC samples of control mice and PLX3397 treated mice. Representative bands of Western blot analysis. The expression of Iba1 in the PFC of PLX3397 treated mice was significantly (P = 0.0023) lower than that of control mice. Data are shown as mean ± SEM. (control group: n = 10, PLX group n = 9). *P < 0.05, **P < 0.01, ***P < 0.001.
Fig. 4 FACS analysis of PFC samples from vehicle or PLX3397 treated mice. a FACS analysis of CD11b-gated cells stained with antibody to TMEM119 in PFC samples of control mice and PLX3397 treated mice. b Iba1 and TGF-β1 expression in TMEM119+CD11b+ microglia were analyzed. Red histograms indicate control group and blue histograms indicate PLX3397 treated group. c The fluorescence intensity of both Iba1 and TGF-β1 in TMEM119+CD11b+ microglia in the PFC of PLX3397 treated mice was significantly (Iba1: P = 0.0186, TGF-β1: P = 0.0002) lower than that of control mice. d Western blot analysis of Iba1 in the PFC samples of control mice and PLX3397 treated mice. Representative bands of Western blot analysis. The expression of Iba1 in the PFC of PLX3397 treated mice was significantly (P = 0.0023) lower than that of control mice. Data are shown as mean ± SEM. (control group: n = 10, PLX group n = 9). *P < 0.05, **P < 0.01, ***P < 0.001.CC BY · PubMed Central
Fig. 5 Effects of PLX3397 on antidepressant effects of (R)-ketamine in a CSDS model. a Chronic social defeat stress (CSDS) was performed from day 1 to day 10 for 10 days. Social interaction test was performed on day 11. On day 12, vehicle or PLX3397 was administered i.c.v. to CSDS susceptible mice. On day 13, saline or (R)-ketamine (10 mg/kg) was administered i.p. 24 h after injection of PLX3397. Locomotion and FST were performed 1 and 3 h after injection, respectively. FST and SPT were performed 1 and 2 days after injection, respectively. b Locomotion (1 h, one-way ANOVA, F4,35 = 0.226, P = 0.921). c TST (3 h, one-way ANOVA, F4,35 = 13.706, P < 0.001). d FST (1 day, one-way ANOVA, F4,35 = 5.362, P = 0.005). e SPT (2 day, one-way ANOVA, F4,35 = 6.045, P = 0.003). Data are shown as mean ± SEM. (n = 8). *P < 0.05, **P < 0.01. ANOVA analysis of variance, FST forced swimming test, N.S. not significant, PLX PLX3397, R-KT (R)-ketamine, SPT sucrose preference test, TST tail suspension test.
Fig. 5 Effects of PLX3397 on antidepressant effects of (R)-ketamine in a CSDS model. a Chronic social defeat stress (CSDS) was performed from day 1 to day 10 for 10 days. Social interaction test was performed on day 11. On day 12, vehicle or PLX3397 was administered i.c.v. to CSDS susceptible mice. On day 13, saline or (R)-ketamine (10 mg/kg) was administered i.p. 24 h after injection of PLX3397. Locomotion and FST were performed 1 and 3 h after injection, respectively. FST and SPT were performed 1 and 2 days after injection, respectively. b Locomotion (1 h, one-way ANOVA, F4,35 = 0.226, P = 0.921). c TST (3 h, one-way ANOVA, F4,35 = 13.706, P < 0.001). d FST (1 day, one-way ANOVA, F4,35 = 5.362, P = 0.005). e SPT (2 day, one-way ANOVA, F4,35 = 6.045, P = 0.003). Data are shown as mean ± SEM. (n = 8). *P < 0.05, **P < 0.01. ANOVA analysis of variance, FST forced swimming test, N.S. not significant, PLX PLX3397, R-KT (R)-ketamine, SPT sucrose preference test, TST tail suspension test.CC BY · PubMed Central
Fig. 6 Effects of recombinant TGF-β1 and TGF-β2 in a CSDS model. a Chronic social defeat stress (CSDS) was performed from day 1 to day 10 for 10 days. Social interaction test was performed on day 11. On day 12, vehicle or TGF-β1 (or TGF-β2) was administered i.c.v. to CSDS susceptible mice. Locomotion and TST were performed 1 and 3 h after injection, respectively. FST was performed 1 day after injection. SPT was performed 2, 4, and 7 days after injection. b Locomotion (1 h, one-way ANOVA, F3,20 = 0.122, P = 0.946). c TST (3 h, one-way ANOVA, F3,20 = 2.352, P = 0.041). d FST (1 day, one-way ANOVA, F3,20 = 3.650, P = 0.030). e SPT (2 day, one-way ANOVA, F3,20 = 3.410, P = 0.037). f SPT (4 day, one-way ANOVA, F3,20 = 8.140, P = 0.001). g SPT (7 day, one-way ANOVA, F3,20 = 6.278, P = 0.004). h Locomotion (1 h, one-way ANOVA, F3,20 = 0.171, P = 0.975). i TST (3 h, one-way ANOVA, F3,20 = 10.093, P < 0.001). j FST (1 day, one-way ANOVA, F3,20 = 16.353, P < 0.001). k SPT (2 day, one-way ANOVA, F3,20 = 4.750, P = 0.012). l SPT (4 day, one-way ANOVA, F3,20 = 5.404, P = 0.007). Data are shown as mean ± SEM. (n = 6). *P < 0.05, **P < 0.01. ANOVA analysis of variance, FST forced swimming test, N.S. not significant, R-KT (R)-ketamine, SPT sucrose preference test, TST tail suspension test.
Fig. 6 Effects of recombinant TGF-β1 and TGF-β2 in a CSDS model. a Chronic social defeat stress (CSDS) was performed from day 1 to day 10 for 10 days. Social interaction test was performed on day 11. On day 12, vehicle or TGF-β1 (or TGF-β2) was administered i.c.v. to CSDS susceptible mice. Locomotion and TST were performed 1 and 3 h after injection, respectively. FST was performed 1 day after injection. SPT was performed 2, 4, and 7 days after injection. b Locomotion (1 h, one-way ANOVA, F3,20 = 0.122, P = 0.946). c TST (3 h, one-way ANOVA, F3,20 = 2.352, P = 0.041). d FST (1 day, one-way ANOVA, F3,20 = 3.650, P = 0.030). e SPT (2 day, one-way ANOVA, F3,20 = 3.410, P = 0.037). f SPT (4 day, one-way ANOVA, F3,20 = 8.140, P = 0.001). g SPT (7 day, one-way ANOVA, F3,20 = 6.278, P = 0.004). h Locomotion (1 h, one-way ANOVA, F3,20 = 0.171, P = 0.975). i TST (3 h, one-way ANOVA, F3,20 = 10.093, P < 0.001). j FST (1 day, one-way ANOVA, F3,20 = 16.353, P < 0.001). k SPT (2 day, one-way ANOVA, F3,20 = 4.750, P = 0.012). l SPT (4 day, one-way ANOVA, F3,20 = 5.404, P = 0.007). Data are shown as mean ± SEM. (n = 6). *P < 0.05, **P < 0.01. ANOVA analysis of variance, FST forced swimming test, N.S. not significant, R-KT (R)-ketamine, SPT sucrose preference test, TST tail suspension test.CC BY · PubMed Central
Fig. 7 Effects of recombinant TGF-β1 in LPS model and LH model. a Saline or LPS (0.5 mg/kg) was administered i.p. to mice. Saline or TGF-β1 was administered i.c.v. to LPS-treated mice 23 h after LPS injection. Locomotion and FST were performed 1 and 3 h after injection, respectively. b Locomotion (1 h, one-way ANOVA, F2,39 = 0.122, P = 0.122). c FST (3 h, one-way ANOVA, F2,39 = 3.124, P = 0.045). Data are shown as mean ± SEM. (n = 14). *P < 0.05. d Saline or LPS (0.5 mg/kg) was administered i.p. to mice. Saline or TGF-β1 was administered intranasally to LPS-treated mice 23 h after LPS injection. Locomotion and FST were performed 1 and 3 h after injection, respectively. e Locomotion (1 h, one-way ANOVA, F2,27 = 0.255, P = 0.777). f FST (3 h, one-way ANOVA, F2,27 = 5.180, P = 0.013). Data are shown as mean ± SEM. (n = 10). *P < 0.05, **P < 0.01. g Rats received inescapable electric stress shock (IES) treatments on 2 days (day 1 and day 2), passed a post-shock test (PS) on day 3 to select learned helplessness (LH) rats with depression-like phenotype. On day 4, vehicle or TGF-β1 was administered i.c.v. into LH rats. On day 8 (4 days after i.c.v. injection), conditioned avoidance (CA) tests to study the antidepressant effect was performed. h The failure number of TGF-β1 treated LH rats was significantly (P = 0.0259) lower than that of vehicle treated LH rats. i The escape latency of TGF-β1 treated LH rats was significantly (P = 0.0281) lower than that of vehicle treated LH rats. Data are shown as mean ± SEM. (vehicle: n = 5, TGF-β1: n = 6). *P < 0.05. FST forced swimming test, N.S. not significant.
Fig. 7 Effects of recombinant TGF-β1 in LPS model and LH model. a Saline or LPS (0.5 mg/kg) was administered i.p. to mice. Saline or TGF-β1 was administered i.c.v. to LPS-treated mice 23 h after LPS injection. Locomotion and FST were performed 1 and 3 h after injection, respectively. b Locomotion (1 h, one-way ANOVA, F2,39 = 0.122, P = 0.122). c FST (3 h, one-way ANOVA, F2,39 = 3.124, P = 0.045). Data are shown as mean ± SEM. (n = 14). *P < 0.05. d Saline or LPS (0.5 mg/kg) was administered i.p. to mice. Saline or TGF-β1 was administered intranasally to LPS-treated mice 23 h after LPS injection. Locomotion and FST were performed 1 and 3 h after injection, respectively. e Locomotion (1 h, one-way ANOVA, F2,27 = 0.255, P = 0.777). f FST (3 h, one-way ANOVA, F2,27 = 5.180, P = 0.013). Data are shown as mean ± SEM. (n = 10). *P < 0.05, **P < 0.01. g Rats received inescapable electric stress shock (IES) treatments on 2 days (day 1 and day 2), passed a post-shock test (PS) on day 3 to select learned helplessness (LH) rats with depression-like phenotype. On day 4, vehicle or TGF-β1 was administered i.c.v. into LH rats. On day 8 (4 days after i.c.v. injection), conditioned avoidance (CA) tests to study the antidepressant effect was performed. h The failure number of TGF-β1 treated LH rats was significantly (P = 0.0259) lower than that of vehicle treated LH rats. i The escape latency of TGF-β1 treated LH rats was significantly (P = 0.0281) lower than that of vehicle treated LH rats. Data are shown as mean ± SEM. (vehicle: n = 5, TGF-β1: n = 6). *P < 0.05. FST forced swimming test, N.S. not significant.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Cited by

See all 119

Metadata

Authors
Zhang, K., Yang, C., Chang, L., Sakamoto, A., Suzuki, T., Fujita, Y., Qu, Y., Wang, S., Pu, Y., Tan, Y., Wang, X., Ishima, T., Shirayama, Y., Hatano, M., Tanaka, K. F., & Hashimoto, K.
Affiliations
  • Chiba University (JP)
  • Keio University (JP)
Corresponding author
Hashimoto, Kenji
Venue
Translational Psychiatry
Published
2020-01-27
Volume
10
Issue
1
Pages
32-32
ISSN
2158-3188 (ISSN-L)
OpenAlex
W3001997868
Cited by
119
References
63
Citations by year
2026: 8 · 2025: 13 · 2024: 25 · 2023: 24 · 2022: 25 · 2021: 13 · 2020: 11
FWCI
10.94
Type
journal article
Language
en
Open access
Licence
Locations
  • Translational Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Japan Agency for Medical Research and Development (JP19dm0107119)
  • MEXT | Japan Society for the Promotion of Science (19K17054)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
(R)-ketamine, esketamine, enantioselectivity, antidepressant effects, TGF-β1, microglia, chronic social defeat stress, depression, prefrontal cortex, hippocampus, TGF-beta receptor, CSF1R inhibition, PLX3397, RepSox, SB431542, rapid-acting antidepressants
MeSH terms
Animals, Antidepressive Agents, Depression, Disease Models, Animal, Ketamine, Mice, Inbred C57BL, Stress, Psychological, Microglia, Mice, Transforming Growth Factor beta1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1. https://app.cochat.ai/papers/10.1038/s41398-020-0733-x
The paper
Zhang, K., Yang, C., Chang, L., Sakamoto, A., Suzuki, T., Fujita, Y., Qu, Y., Wang, S., Pu, Y., Tan, Y., Wang, X., Ishima, T., Shirayama, Y., Hatano, M., Tanaka, K. F., & Hashimoto, K. (2020). Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1. Translational Psychiatry. https://doi.org/10.1038/s41398-020-0733-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.